Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837019 | 0.90 | POLB (0.36) | NPC1MEN1KMT2ATSHRPOLB | |
| SCHEMBL12755486 | 0.81 | NPC1 (0.37) | NPC1TSHRPOLBL3MBTL1ACHE | |
| SCHEMBL27963127 | 0.79 | NPC1 (0.36) | NPC1TSHRPOLBL3MBTL1ACHE | |
| SCHEMBL19105275 | 0.79 | ACHE (0.36) | NPC1TSHRPOLBL3MBTL1ACHE | |
| SCHEMBL18171391 | 0.78 | CYP4F2 (0.41) | NPC1TSHRPOLBL3MBTL1ZDHHC20 | |
| SCHEMBL27657800 | 0.77 | NPC1 (0.41) | NPC1TSHRPOLBL3MBTL1ACHE | |
| SCHEMBL2478567 | 0.77 | NPC1 (0.41) | NPC1TSHRPOLBL3MBTL1ACHE | |
| SCHEMBL17914698 | 0.76 | NPC1 (0.34) | NPC1TSHRPOLBL3MBTL1ZDHHC20 | |
| SCHEMBL28571907 | 0.76 | NPC1 (0.34) | NPC1TSHRPOLBL3MBTL1ZDHHC20 | |
| SCHEMBL18175903 | 0.76 | NPC1 (0.34) | NPC1MEN1KMT2ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101787135-B | Reticular polymer gel based on polyethylene glycol and preparation method thereof | UNIV SOUTHEAST | 2013-01-02 | — | — | CN | claimed |
| CN-101787135-A | Reticular polymer gel based on polyethylene glycol and preparation method thereof | UNIV SOUTHEAST | 2010-07-28 | — | — | CN | claimed |
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-110734536-A | preparation method of environment-friendly fluorine-containing waterborne polyurethane | 临沂大学 | 2020-01-31 | — | — | CN | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9579391-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| CN-105753965-A | Conjugate Based Systems For Controlled Drug Delivery | 斯马特塞尔斯公司 | 2016-07-13 | — | — | CN | disclosed |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9265838-B2 | Conjugate based systems for controlled drug delivery | SMART CELLS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| CN-101787135-A | Reticular polymer gel based on polyethylene glycol and preparation method thereof | UNIV SOUTHEAST | 2010-07-28 | — | — | CN | disclosed |
| CN-100448841-C | Process for preparing 2-cyclohexenone compounds | UNIV ZHEJIANG (CN) | 2009-01-07 | — | — | CN | disclosed |
| CN-101104587-A | 2-cyclohexenone compounds | UNIV ZHEJIANG (CN) | 2008-01-16 | — | — | CN | disclosed |
| CN-100358857-C | 2-cyclohexenone compounds and preparation method thereof | UNIV ZHEJIANG (CN) | 2008-01-02 | — | — | CN | disclosed |
| CN-1951903-A | Process for preparing 2-cyclohexenone compounds | UNIV ZHEJIANG (CN) | 2007-04-25 | — | — | CN | disclosed |
| CN-1827577-A | 2-cyclohexenone compounds and preparation method thereof | UNIV ZHEJIANG (CN) | 2006-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | NPC1 843/4885MEN1 1908/4885KMT2A 3261/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | NPC1 843/4885MEN1 1908/4885KMT2A 3261/4885 |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | NPC1 843/4885MEN1 1908/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.